|Bid||0.5200 x 0|
|Ask||0.5600 x 0|
|Day's Range||0.5200 - 0.5600|
|52 Week Range||0.5000 - 0.9200|
|Beta (5Y Monthly)||1.47|
|PE Ratio (TTM)||26.00|
|Earnings Date||Nov. 17, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
\- Access the event and schedule of presenting companies at virtualinvestorco.com -\- Live video webcast presentations of participating companies followed by interactive Q&A session -PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 /JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2022 Top Picks Conference January 25-27, 2022.
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
– PGX Technology further recognized as a disruptive technology – Additional support paves the way for the manufacturing of pharmaceutical-grade yeast beta glucan (YBG) EDMONTON, Alberta, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced they are receiving advisory services and up to